Alnylam Pharmaceuticals cut to hold from buy by Truist; target price lowered to $225 from $315
ALNY•Truist Securities cut its rating on Alnylam Pharmaceuticals to hold from buy and lowered its target price to $225 from $315.
Related News
Nasdaq trade halt: volatility trading pause at 9:31 a.m.
AZR•
Cyabra secures six-figure contract with leading Southeast Asian national investigative agency
CYAB•
UBS raises American Express target price to $346 from $345
AXP•
CSB Bancorp CFO Paula J. Meiler plans to retire April 30, 2027
CSBB•
Canadian factory PMI shows sector contracting for first time in 2026
TLT•